LTIP839A - Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof - Google Patents

Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof

Info

Publication number
LTIP839A
LTIP839A LTIP839A LTIP839A LTIP839A LT IP839 A LTIP839 A LT IP839A LT IP839 A LTIP839 A LT IP839A LT IP839 A LTIP839 A LT IP839A LT IP839 A LTIP839 A LT IP839A
Authority
LT
Lithuania
Prior art keywords
memantine
solid pharmaceutical
extended
production
dosage forms
Prior art date
Application number
LTIP839A
Other languages
Lithuanian (lt)
Inventor
Eberhard Nurnberg
Erhard Seiller
Stefan Ritsert
Original Assignee
Merz Pharma Gmbh & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co. Kgaa filed Critical Merz Pharma Gmbh & Co. Kgaa
Publication of LTIP839A publication Critical patent/LTIP839A/en
Publication of LT3201B publication Critical patent/LT3201B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Šis išradimas apima kietas farmacines kompozicijas dozuotoje formoje, turinčias aktyvų ingredientą arba pagrindą, ypač memantiną, kurios įgyvendinta prailgintą dviejų fazių vaisto išskyrimą, ir kurios yra charakterizuojamos buvimu matricoje dviejų - vandenyje tirpios ir vandenyje netirpios kazeino druskos, ypač natrio ir kalcio kazeinatų plačiose proporcijų ribose , o jų bendras kiekis kompozicijoje yra tarp 5 ir 98 masės %, ir jų gavimo būdą.The present invention relates to solid pharmaceutical compositions in dosage form comprising an active ingredient or a base, in particular memantine, which is provided by extended release of the two-phase drug, and which are characterized by the presence in the matrix of two - water-soluble and water-insoluble casein salts, in particular in the broad proportions of sodium and calcium caseinates, in particular in the broad proportions. and their total content in the composition is between 5 and 98% by weight, and the method of preparation.

LTIP839A 1992-08-04 1993-08-04 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof LT3201B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4225730A DE4225730C2 (en) 1992-08-04 1992-08-04 Process for the preparation of solid dosage forms with protracted 2-stage release

Publications (2)

Publication Number Publication Date
LTIP839A true LTIP839A (en) 1994-08-25
LT3201B LT3201B (en) 1995-03-27

Family

ID=6464804

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP839A LT3201B (en) 1992-08-04 1993-08-04 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof

Country Status (17)

Country Link
US (1) US5382601A (en)
EP (1) EP0582186B1 (en)
JP (1) JP3560244B2 (en)
CN (1) CN1086708A (en)
AT (1) ATE176866T1 (en)
AU (1) AU669731B2 (en)
CA (1) CA2141691C (en)
DE (2) DE4225730C2 (en)
DK (1) DK0582186T3 (en)
ES (1) ES2128369T3 (en)
GR (1) GR3030227T3 (en)
IL (1) IL106580A (en)
LT (1) LT3201B (en)
LV (1) LV10182B (en)
MX (1) MX9304675A (en)
WO (1) WO1994003158A1 (en)
ZA (1) ZA935614B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
AU3860797A (en) * 1997-07-16 1999-02-10 Antrin Research Limited Pharmaceutical formulations for oral administration
US5840334A (en) * 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
DE19809242A1 (en) * 1998-03-05 1999-09-09 Basf Ag Process for the production of solid, spherical shaped articles containing pharmaceutical active substances in a binder matrix
DE19814257A1 (en) * 1998-03-31 1999-10-07 Asta Medica Ag effervescent formulations
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
EP1852113A3 (en) * 2000-12-07 2008-03-12 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
WO2005079773A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2006096194A2 (en) * 2004-06-17 2006-09-14 Merz Pharma Gmbh & Co. Kgaa Drinkable immediate release tablet made with direct compression of memantine or neramexane
US8039009B2 (en) * 2004-06-17 2011-10-18 Forest Laboratories Holdings Limited Modified release formulations of memantine oral dosage forms
KR100901927B1 (en) * 2004-06-17 2009-06-10 메르츠 파마 게엠베하 운트 코. 카가아 Drinkable immediate release formulations prepared by direct compression of memantine or neramexane
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
KR101301429B1 (en) * 2004-11-23 2013-08-30 아다마스 파마슈티칼스, 인코포레이티드 Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
JP5597343B2 (en) * 2005-04-28 2014-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition containing anti-dementia drug
US20060286167A1 (en) * 2005-05-02 2006-12-21 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
CA2607600A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
CA2634507A1 (en) * 2005-12-23 2007-06-28 Alk-Abello A/S Method for dissolution testing of pharmaceutical products
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
US7624743B2 (en) * 2006-09-14 2009-12-01 Halliburton Energy Services, Inc. Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2583669A1 (en) 2007-10-10 2013-04-24 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
TWI478712B (en) 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
EP2363119A1 (en) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers New pharmaceutical composition suitable for treating persons affected by neurodegenerative or neurovascular diseases
WO2012101653A2 (en) 2011-01-25 2012-08-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
WO2012110912A1 (en) 2011-02-17 2012-08-23 Lupin Limited Sustained release composition of memantine
TR201104108A2 (en) 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Prolonged release memantine tablets.
FR2980973B1 (en) * 2011-10-11 2013-11-15 Univ Clermont Auvergne COMPOSITION FOR THE PROPHYLACTIC TREATMENT OF NEUROPATHIC PAIN.
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
WO2014028878A1 (en) 2012-08-16 2014-02-20 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
CN105121559A (en) * 2013-02-08 2015-12-02 巴斯夫欧洲公司 Production of inorganic/organic composite materials by reactive spray drying
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
MX2020002078A (en) 2017-08-24 2020-09-21 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use.
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US11602507B2 (en) 2019-05-27 2023-03-14 Trikona Pharmaceuticals Pvt. Ltd Extended release oral composition of memantine or its salt and its process for the preparation
CU24720B1 (en) 2020-11-24 2024-10-09 Centro De Neurociencias De Cuba PHARMACEUTICAL COMPOSITION OF NAPHTHALENE DERIVATIVES AS MULTITARGET THERAPEUTIC AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
EP4678167A1 (en) * 2024-07-04 2026-01-14 Laboratorio della Farmacia S.p.A. Solid oral composition with gradual enteric release for lipophilic active ingredients

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB715874A (en) * 1952-10-03 1954-09-22 Horlicks Ltd A tablet for use in treating peptic ulcers
GB840091A (en) * 1955-09-08 1960-07-06 Upjohn Co Improvements in or relating to therapeutic compositions and the manufacture thereof
US3594467A (en) * 1968-10-09 1971-07-20 Richardson Merrell Inc Long-lasting troche
ES413944A1 (en) * 1972-04-20 1976-06-01 Merz & Co Drugs or medicines for influencing the central nervous system
US4076846A (en) * 1974-11-22 1978-02-28 Sumitomo Bakelite Company Limited Protein-starch binary molding composition and shaped articles obtained therefor
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4419369A (en) * 1980-09-22 1983-12-06 Baylor College Of Medicine Protein mineral dietary module
US4346112A (en) * 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS59101423A (en) * 1982-12-02 1984-06-12 Takada Seiyaku Kk Novel solid pharmaceutical preparation of nifedipine
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
AU593821B2 (en) * 1985-08-06 1990-02-22 Excel Technologies International Corporation Treating agent for liquid media
US4897380A (en) * 1985-08-30 1990-01-30 Pollack Robert L Method and composition for relieving dietary-related disorders
US4853377A (en) * 1985-10-15 1989-08-01 Pollack Robert L Method and composition for increasing production of serotonin
DK179687D0 (en) * 1987-04-08 1987-04-08 Farma Food As PREPARATION
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
DE58905637D1 (en) * 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Use of adamantane derivatives for the prevention and treatment of cerebral ischemia.
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
WO1991017745A1 (en) * 1990-05-23 1991-11-28 Southwest Research Institute Filament system for delivering a medicament and method
FR2664499B1 (en) * 1990-07-16 1994-11-04 Jacques Dubois NOVEL PHARMACEUTICAL FORMS, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS.

Also Published As

Publication number Publication date
JP3560244B2 (en) 2004-09-02
IL106580A0 (en) 1993-12-08
MX9304675A (en) 1994-03-31
DE4225730A1 (en) 1994-02-10
GR3030227T3 (en) 1999-08-31
DE59309388D1 (en) 1999-04-01
DE4225730C2 (en) 2003-04-30
JPH07509479A (en) 1995-10-19
IL106580A (en) 1998-02-08
US5382601A (en) 1995-01-17
CN1086708A (en) 1994-05-18
EP0582186B1 (en) 1999-02-24
AU669731B2 (en) 1996-06-20
EP0582186A1 (en) 1994-02-09
ATE176866T1 (en) 1999-03-15
LV10182A (en) 1994-10-20
CA2141691A1 (en) 1994-02-17
LT3201B (en) 1995-03-27
DK0582186T3 (en) 1999-09-27
AU4706993A (en) 1994-03-03
ZA935614B (en) 1995-02-03
CA2141691C (en) 2002-04-09
WO1994003158A1 (en) 1994-02-17
LV10182B (en) 1995-04-20
ES2128369T3 (en) 1999-05-16

Similar Documents

Publication Publication Date Title
LTIP839A (en) Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof
FI942092A7 (en) Government-approved product
HRP20010243B1 (en) PREPARATIONS CONTAINING DIPHOSPHONIC ACIDS
ATE362755T1 (en) STABLE COMPOSITIONS CONTAINING N-PROPARGYL-1-AMINOINDANE
ATE158504T1 (en) EFFORTABLE MIXTURES CONTAINING IBUPROFEN AND METHODS
UA26455C2 (en) MEDICINAL PRODUCT IN THE FORM OF TABLETS WITH SLOW RELEASE OF THE ACTIVE INGREDIENT
HUT60466A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
ES541521A0 (en) A PROCEDURE FOR THE PREPARATION OF PIRIDAZINAMINES.
ES2002140A6 (en) Transdermally resorbable aqueous compositions of arylpropionic-acid derivatives and process for their preparation.
DE69635996D1 (en) PHARMACEUTICAL COMPOSITIONS WITH HYDROXIC ACID DERIVATIVES
ATE225649T1 (en) MEDICINAL PREPARATION CONSISTING OF RHEIN OR DIACERHEIN WITH IMPROVED BIOAVAILABILITY
ES2115616T3 (en) USE OF INOSITOLTRISPHOSPHATE IN THE PREPARATION OF MEDICINES.
ATE79538T1 (en) DISPERSABLE PREPARATION.
FI972434A0 (en) Lamotrigine-containing pharmaceutical composition
ES2062137T3 (en) USE OF 5'-DEOXI-5'-METHYL-THIOADENOSINE, S-ADENOSYLMETIONINE AND ITS SALTS FOR THE PREPARATION OF REDUCING PHARMACEUTICAL COMPOSITIONS OF SEBORRHEA.
KR970705998A (en) 2-diaminopyrimidine 3-oxide or a salt thereof (USE OF 2,4-DIAMINO PYRIMIDINE 3-OXIDE OR A SALT THEREOF FOR TREATING COLLAGEN MATURATION AND STRUCTURING DISORDERS)
HUP9902415A2 (en) Solid instant-release forms of administration and process for producing the same
ES2052000T3 (en) PROCEDURE FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING PENTAMIDINE.
DK0414115T3 (en) Auxiliary free rib flea granules
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
NO973401L (en) Corticosteroid-containing compositions and their preparation
CA2429793A1 (en) Interferon therapeutic effect enhancer
FR2684878B1 (en) STABILIZED PHARMACEUTICAL COMPOSITION OF RECOMBINANT, NON-GLYCOSYLATED HUMAN IL2 IN REDUCED FORM AND PROCESS FOR PREPARING THE SAME.
CA2001568A1 (en) Medicament for treating toxoplasmosis
RU95109891A (en) 19,11-overbriged 4-estrenes, method for their production, pharmaceutical composition comprising them and intermediate compounds for their production

Legal Events

Date Code Title Description
TK9A Rectifications: patents

Free format text: MERZ + CO. GMBH & CO., ECKENHEIMER LANDSTRASSE 100-104, D-6000 FRANKFURT AM MAIN 1, DE, 19951128

PD9A Change of patent owner

Owner name: MERZ PHARMA GMBH & CO. KGAA,DE

Effective date: 20021017

MK9A Expiry of a patent

Effective date: 20130804